Sundar Jagannath

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

Faith Davies, Edie Weller, Kenneth Anderson, 2004, Mayo Clinic proceedings.

An inflammatory cytokine signature predicts COVID-19 severity and survival

Keith Sigel, Patricia Kovatch, Miriam Merad, 2020, Nature Medicine.

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

Kenneth C. Anderson, Joi Dunbar, S. Jagannath, 2011, Leukemia & lymphoma.

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Hartmut Goldschmidt, Meral Beksaç, Mario Boccadoro, 2011, Blood.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Hans Erik Johnsen, Giampaolo Merlini, Robert A Kyle, 2014, The Lancet. Oncology.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bart Barlogie, Gordan Srkalovic, David Irwin, 2003, The New England journal of medicine.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Diane Warren, Edie Weller, S. Jagannath, 2006, Blood.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Bin Li, Matthew Schu, R. Neuwirth, 2014, Blood.